Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for Eton Pharmaceuticals (ETON) over the last 6 years, with Mar 2025 value amounting to $394,000.

  • Eton Pharmaceuticals' Cash from Financing Activities rose 204.23% to $394,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $33.4 million, marking a year-over-year increase of 2694.48%. This contributed to the annual value of $32.6 million for FY2024, which is 3505.75% up from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Cash from Financing Activities of $394,000 as of Q1 2025, which was down 98.83% from $33.6 million recorded in Q4 2024.
  • Over the past 5 years, Eton Pharmaceuticals' Cash from Financing Activities peaked at $33.6 million during Q4 2024, and registered a low of -$385,000 during Q1 2022.
  • Over the past 3 years, Eton Pharmaceuticals' median Cash from Financing Activities value was -$245,000 (recorded in 2023), while the average stood at $3.6 million.
  • Per our database at Business Quant, Eton Pharmaceuticals' Cash from Financing Activities plummeted by 1,154.29% in 2023 and then surged by 11,519.05% in 2024.
  • Quarterly analysis of 5 years shows Eton Pharmaceuticals' Cash from Financing Activities stood at $68,000 in 2021, then skyrocketed by 45.59% to $99,000 in 2022, then tumbled by 396.97% to -$294,000 in 2023, then skyrocketed by 11,519.05% to $33.6 million in 2024, then spiked by 204.23% to $394,000 in 2025.
  • Its Cash from Financing Activities stands at $394,000 for Q1 2025, versus $33.6 million for Q4 2024 and -$385,000 for Q3 2024.